Cargando…

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)

Background: In people with overweight/obesity and type 2 diabetes (T2D), achievement of weight loss can be a challenge. STEP 2 investigated the efficacy and safety of semaglutide 2.4 mg for weight management in adults with overweight/obesity and T2D. Methods: This randomized, double-blind, double-du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089158/ http://dx.doi.org/10.1210/jendso/bvab048.019

Ejemplares similares

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial
por: Fox, Claudia K, et al.
Publicado: (2021)

A Novel Variant of the SH2B1 Gene in an Obese Child With Type 2 Diabetes
por: Morillo, Mariaester Makacio, et al.
Publicado: (2021)

Antiandrogens Target TMPRSS2 and Reduce SARS-CoV-2 Virus Entry in Lung Cells
por: Leach, Damien A, et al.
Publicado: (2021)

PSUN97 Regulation of melanocortin-3 and -4 receptors by isoforms of melanocortin-2 receptor accessory protein 1 and 2
por: Ji, Ren-Lei, et al.
Publicado: (2022)

Inhibition of CXCR2 by Glucocorticoids in Adipose Tissue
por: Amatya, Shripa, et al.
Publicado: (2021)

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity
por: Ji, Linong, et al.
Publicado: (2022)

SUN-110 The Role Of RasD2 In Metabolism And Obesity
por: Fong, Vincent, et al.
Publicado: (2019)

OR12-2 Obesity Induces Changes in T Cell Metabolism and Function
por: Alwarawrah, Yazan, et al.
Publicado: (2019)

SUN-586 CXCR2 Repression by Glucocorticoids in Adipose Tissue
por: Amatya, Shripa, et al.
Publicado: (2020)

PSUN81 A novel case of congenital generalized lipodystrophy (CGL) with no genetic abnormalites in the AGPAT2, BSCL2, CAV1, and CAVIN1 genes.
por: Mericq, Veronica, et al.
Publicado: (2022)

MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) Inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic Review and Meta-Analysis
por: Cabrera, Carmen Carina, et al.
Publicado: (2020)

Incidence of Insulin Resistance in Obese Adolescent of Type-2 Diabetes Mellitus Patients
por: Javaid, Farrukh, et al.
Publicado: (2021)

Early Follow-up of Atypical Thyroiditis Induced by SARS-CoV-2
por: Muller, Ilaria, et al.
Publicado: (2021)

BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH
por: Frias, Juan Pablo, et al.
Publicado: (2021)

SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

SUN-LB101 NRF2 Represses Obesity-Associated Adipose Tissue Inflammation in Mice
por: Yagishita, Yoko, et al.
Publicado: (2020)

OR33-07 ARNT2: A Potential Novel Candidate Gene for Monogenic Obesity in Humans
por: Thaker, Vidhu V, et al.
Publicado: (2020)

FRI013 Free Fatty Acid Receptors 2 And 3 Mediate The Beneficial Effects Of Fiber
por: Pandya, Nupur S, et al.
Publicado: (2023)

FRI012 Exploring The Role Of FFA2 In Western Diet-induced Obesity And Metabolic Changes
por: Nnyamah, Christine, et al.
Publicado: (2023)

FRI073 Use Of Obesogenic Medications Among Patients With Type 2 Diabetes In The Dominican Republic
por: Agramonte Villar, Scarlet P, et al.
Publicado: (2023)

SUN-LB019 Myeloid Krüppel-like Factor 2 is a Critical Regulator of Metabolic Inflammation
por: Sweet, David, et al.
Publicado: (2019)

MON-LB102 Metformin-Induced Weight Loss in Patients With or Without Type 2 Diabetes/Prediabetes
por: Chukir, Tariq, et al.
Publicado: (2020)

TNF Alpha-Induced SOX2 Expression Promotes Hepatic Steatois in Diet-Induced Obesity Model
por: Shen, Chen, et al.
Publicado: (2021)

PSUN82 The Gut Microbiome Regulates Healthy Adipose Tissue Expansion via the Action of FFA2
por: Nnyamah, Christine, et al.
Publicado: (2022)

MON-118 Biochemical and Clinical Correlates of Subcutaneous Adipose mRNA Transcript Levels in Men with T2DM
por: Tun, Nyo Nyo, et al.
Publicado: (2019)

OR04-01 MRAP2 Regulates Energy Homeostasis by Promoting Primary Cilia Localization of MC4R
por: Bernard, Adelaide A, et al.
Publicado: (2020)

Type 2 Diabetes Mellitus Remission in Obese Patients Under Bariatric Surgery: The Role of Preoperative Triglycerides Levels
por: Gonçalves, Vanessa Guerreiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6f01d0t1o6bnrjo3tmf2b18qnc